

20 Jan 2026
// BUSINESSWIRE
https://www.businesswire.com/news/home/20260120542667/en/Lantern-Pharmas-LP-284-Receives-FDA-Orphan-Drug-Designation-for-Soft-Tissue-Sarcomas

28 Oct 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20251028963039/en/Lantern-Pharma-Presents-LP-284-Clinical-Data-at-25th-LLM-Congress-Highlighting-Complete-Response-in-Therapeutically-Exhausted-DLBCL-Patient-Therapeutic-Potential-in-Advanced-B-Cell-Cancers.